NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models-Reference-Cited by-同舟云学术

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Published:2008-04 Issue:2 Volume:10 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Jensen Michael Rugaard,Schoepfer Joseph,Radimerski Thomas,Massey Andrew,Guy Chantale T,Brueggen Josef,Quadt Cornelia,Buckler Alan,Cozens Robert,Drysdale Martin J,Garcia-Echeverria Carlos,Chène Patrick

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr1996.pdf

Reference35 articles.

1. Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005, 105: 2640-2653. 10.1182/blood-2004-08-3097.

2. Herbst RS, Fukuoka M, Baselga J: Gefitinib – a novel targeted approach to treating cancer. Nat Rev Cancer. 2004, 4: 956-965. 10.1038/nrc1506.

3. Adams GP, Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005, 23: 1147-1157. 10.1038/nbt1137.

4. Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M: Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer. 2007, 43: 497-509. 10.1016/j.ejca.2006.10.020.

5. Workman P, Burrows F, Neckers L, Rosen N: Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci. 2007, 1113: 202-216. 10.1196/annals.1391.012.

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and antitumor activity of 3,4,5-Trisubstituted Isoxazoles;European Journal of Medicinal Chemistry Reports;2024-12

2. Exploring the Diverse Biological Frontiers of Isoxazole: A Comprehensive Review of its Pharmacological Significance;ChemistrySelect;2024-08-22

3. Activity-based protein profiling and global proteome analysis reveal MASTL as a potential therapeutic target in gastric cancer;Cell Communication and Signaling;2024-08-14

4. An update on the status of HSP90 inhibitors in cancer clinical trials;Cell Stress and Chaperones;2024-08

5. Synthesis and evaluation of isoxazole derivatives of lapachol as inhibitors of pyruvate kinase M2;Synthetic Communications;2024-07-28